Evolution of SLEDAI, anti-dsDNA antibodies and C3 levels at 6, 12 and 24 months of belimumab and its significance compared to baseline values.
| Baseline | 6 months | 12 months | 24 months | |
|---|---|---|---|---|
| SLEDAI - mean±SD | 8.2±3.9 | 3.8±2.2 (p<0.001) | 4.1±3.2 (p<0.001) | 3.1±1.6 (p=0.002) |
| Anti-dsDNA antibodies (UI/mL) - mean±SD | 231.6±238.3 | 155.3±198.7 (p=0.025) | 157.9±341.1 (p=0.031) | 107.4±132.2 (p=0.003) |
| C3 (mg/dL) - mean±SD | 82.6±28.8 | 89.6±27.1 (p=0.223) | 94.6±25.8 (p=0.018) | 100.9±36.9 (p=0.139) |